These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 19882901)

  • 1. [Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].
    Barkhaleva OA; Ladyzhenskaia IP; Vorob'eva MS; Shalunova NV; Podcherniaeva RIa; Mikhaĭlova GR; Khorosheva TV; Barinskiĭ IF
    Vopr Virusol; 2009; 54(5):33-7. PubMed ID: 19882901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicentre clinical trial with herpes simplex virus vaccine in recurrent herpes infection.
    Mastrolorenzo A; Tiradritti L; Salimbeni L; Zuccati G
    Int J STD AIDS; 1995; 6(6):431-5. PubMed ID: 8845402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An escalating dose study to assess the safety, tolerability and immunogenicity of a Herpes Simplex Virus DNA vaccine, COR-1.
    Dutton JL; Woo WP; Chandra J; Xu Y; Li B; Finlayson N; Griffin P; Frazer IH
    Hum Vaccin Immunother; 2016 Dec; 12(12):3079-3088. PubMed ID: 27580249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A killed commercial vaccine against herpes simplex viruses 1 and 2 as an immunocorrective agent in chronic herpetic infection].
    Barinskiĭ IF; Kasparov AA; Lazarenko AA; Alimbarova LM; Davydova AA; Belkina IV; Platonova AL
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (6):98-102. PubMed ID: 10876868
    [No Abstract]   [Full Text] [Related]  

  • 10. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
    Pepose JS; Keadle TL; Morrison LA
    Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genital herpes vaccines--cause for cautious optimism.
    Haddow LJ; Mindel A
    Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunobiology of herpes simplex virus (HSV) infections.
    Corey L
    Herpes; 2001 Mar; 8 Suppl 1():1A. PubMed ID: 11867026
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
    Manservigi R; Boero A; Argnani R; Caselli E; Zucchini S; Miriagou V; Mavromara P; Cilli M; Grossi MP; Balboni PG; Cassai E
    Vaccine; 2005 Jan; 23(7):865-72. PubMed ID: 15603886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Status of vaccine research and development of vaccines for herpes simplex virus.
    Johnston C; Gottlieb SL; Wald A
    Vaccine; 2016 Jun; 34(26):2948-2952. PubMed ID: 26973067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher Throughput Quantification of Neutralizing Antibody to Herpes Simplex Viruses.
    Blevins TP; Mitchell MC; Korom M; Wang H; Yu Y; Morrison LA; Belshe RB
    PLoS One; 2015; 10(12):e0144738. PubMed ID: 26658766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
    Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R
    Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs.
    Bourne N; Bravo FJ; Francotte M; Bernstein DI; Myers MG; Slaoui M; Stanberry LR
    J Infect Dis; 2003 Feb; 187(4):542-9. PubMed ID: 12599070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tale of 2 alpha-herpesviruses: lessons for vaccinologists.
    Rouse BT; Kaistha SD
    Clin Infect Dis; 2006 Mar; 42(6):810-7. PubMed ID: 16477558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HSV-1 herpes vaccination by LUPIDON H: preliminary results.
    De Maria A; Tundo P; Romano A; Grima P
    Adv Exp Med Biol; 1995; 371B():1599-600. PubMed ID: 7502864
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.